Investigation of 1q21 amplification in patients with multiple myeloma using I-FISH and cIg-FISH.
- Author:
Rui-fang YANG
1
;
Chun-ming LI
;
Hai-rong QIU
;
Hua LU
;
Han-xin WU
;
Jia-ren XU
;
Peng ZHANG
;
Jian-yong LI
;
Li-juan CHEN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Chromosomes, Human, Pair 1; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; methods; Male; Middle Aged; Multiple Myeloma; diagnosis; genetics; metabolism; Neoplasm Staging; Prognosis; Syndecan-1; metabolism
- From: Chinese Journal of Medical Genetics 2011;28(6):686-689
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the prevlance of 1q21 amplification in patients with multiple myeloma (MM) and its correlation with the progression and prognosis of the disease.
METHODS1q21 amplification was detected in 48 patients with MM using cytoplasmic light chain immunofluorescence with fluorescence in situ hybridization analysis (cIg-FISH) and interphase fluorescence in situ hybridization (I-FISH) analysis combined with CD138 immunomagnetic cell sorting (MACS).
RESULTS1q21 amplification (≥ 3 red signals) was detected in 26/48(54.2%) cases by cIg-FISH and 31/48 (64.6%) cases by I-FISH combined with CD138 MACS. There was a good consistency between the two methods (P>0.05). The mortality of patients with 1q21 amplification was significantly higher than those without (P< 0.05). No significant difference was detected in terms of sex, age, Durie-Salmon stage, subgroup and international staging system (ISS) stage between patients with 1q21 amplification and those without (P>0.05).
CONCLUSIONThe frequency of 1q21 amplification in MM is high. There was also an association between the amplification and poor prognosis. cIg-FISH is consistent with CD138 MACS combined with I-FISH.
